Boston Scientific gets preliminary FTC okay
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of ICD manufacturer Guidant moves closer to completion after Boston Scientific inked an agreement with Federal Trade Commission staff on April 5. The firm says the consent decree resolves all outstanding U.S. government antitrust issues but still requires final sign-off from FTC commissioners. On or around April 7, the firm will withdraw and re-file its antitrust notification with the agency, giving commissioners 30 days to review the details of the new agreement. Boston Scientific also is awaiting the completion of an antitrust review by the Eur-opean Commission, which will likely push final closing of the deal to mid-April (1"The Gray Sheet" April 3, 2006, p. 3)...
You may also be interested in...
Final Countdown For Blockbuster Boston Scientific Deal
European Commission (EC) antitrust regulators signed off, with some conditions, on Boston Scientific's acquisition of Guidant April 11, leaving U.S. clearance as the only remaining hurdle to closing the deal
Boston Scientific Acquisition Vote Follows Week Of Bad News For Guidant
Boston Scientific and Guidant shareholders approved the merger of their companies in separate votes March 31, leaving U.S. and European antitrust clearances as the only remaining hurdles to closing the deal
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.